eTheRNA Announces Relocation and Expansion of R&D Facility
GENT, BELGIUM, April 5, 2022 – eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is pleased to announce the relocation of its R&D group to a new and larger site in Gent, Belgium.
The upgraded R&D facility is in the Zwijnaarde Science Park, where a cluster of biotech companies are located, and includes state-of-the-art laboratories together with allied services. The increased capacity available will allow eTheRNA’s research departments to enhance their investigations on a variety of mRNA and lipid nanoparticles for R&D applications, resulting in improved control and faster production cycles.